Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells

International Journal of Cancer

Volumn 138, Issue 2, 2016, Pages 497-506

  Weiß, Lilly Magdalena ^a,b   Hugle, Manuela ^a   Romero, Sarah ^a   Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

apoptosis; BCL 2 proteins; Ewing sarcoma; PLK1

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE; TUBULIN MODULATOR; VOLASERTIB;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BONE TUMOR; DRUG EFFECTS; DRUG POTENTIATION; EWING SARCOMA; HUMAN; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; RNA INTERFERENCE; SARCOMA, EWING; TUBULIN MODULATORS;

EID: 84955732600     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29725     Document Type: Article

References (30)

1. Potratz J, Dirksen U, Jurgens H, et al., Ewing sarcoma: clinical state-of-the-art. Pediatr Hematol Oncol 2012; 29: 1-11.
2. Fulda S., Tumor resistance to apoptosis. Int J Cancer 2009; 124: 511-15.
3. Kontny U., Regulation of apoptosis and proliferation in Ewing's sarcoma-opportunities for targeted therapy. Hematol Oncol 2006; 24: 14-21.
4. Scotlandi K., Targeted therapies in Ewing's sarcoma. Adv Exp Med Biol 2006; 587: 13-22.
5. Picarda G, Lamoureux F, Geffroy L, et al., Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res 2010; 16: 2363-74.
6. Fulda S, Debatin KM., Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-811.
7. Taylor RC, Cullen SP, Martin SJ., Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9: 231-41.
8. Adams JM, Cory S., The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-37.
9. Fulda S, Galluzzi L, Kroemer G., Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9: 447-64.
10. Strebhardt K., Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9: 643-60.
11. Hu K, Lee C, Qiu D, et al., Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009; 8: 3024-35.
12. Craig SN, Wyatt MD, McInnes C., Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov 2014; 9: 773-89.
13. Gjertsen BT, Schoffski P., Discovery and development of the polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 2015; 29: 11-19.
14. Gorlick R, Kolb EA, Keir ST, et al., Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2014; 61: 158-64.
15. Le Deley MC, Paulussen M, Lewis I, et al., Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol 2014; 32: 2440-8.
16. Fulda S, Sieverts H, Friesen C, et al., The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-9.
17. Hugle M, Fulda S., Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma. Cancer Lett 2015; 360: 1-9.
18. Naumann I, Kappler R, von Schweinitz D, et al., Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin Cancer Res 2011; 17: 3204-18.
19. Rapino F, Naumann I, Fulda S., Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation. Cell Death Dis 2013; 4: e925.
20. Chou TC., The median-effect principle and the combination index for quantitation of synergism and antagonism. In:, Chou TC, eds. Synergism and antagonism in chemotherapyed. San Diego, USA: Academic Press, 1991. 61-102.
21. Jain S, Vahdat LT., Eribulin mesylate. Clin Cancer Res 2011; 17: 6615-22.
22. Fulda S, Kufer MU, Meyer E, et al., Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001; 20: 5865-77.
23. Kontny HU, Hammerle K, Klein R, et al., Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Cell Death Differ 2001; 8: 506-14.
24. Hans F, Dimitrov S., Histone H3 phosphorylation and cell division. Oncogene 2001; 20: 3021-7.
25. Wertz IE, Kusam S, Lam C, et al., Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110-14.
26. Harley ME, Allan LA, Sanderson HS, et al., Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J 2010; 29: 2407-20.
27. Eichhorn JM, Sakurikar N, Alford SE, et al., Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death. Cell Death Dis 2013; 4: e834.
28. Terrano DT, Upreti M, Chambers TC., Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 2010; 30: 640-56.
29. Hugle M, Belz K, Fulda S., Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs. Cell Death Differ, 2015 May 29 [E-pub ahead of print]
30. Yim H., Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs 2013; 24: 999-1006.